On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
about
Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyKASL clinical practice guidelines: management of chronic hepatitis BBaseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.Management of hepatitis B in developing countries.Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B.Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients.Elecsys hepatitis B surface antigen quantitative assay: performance evaluation and correlation with hepatitis B virus DNA during 96 weeks of follow-up in chronic hepatitis B patients.Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.HBsAg Quantification in Clinical Practice.Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review.Hepatitis B virus serology to predict antiviral response in chronic hepatitis B.Clinical implications of HBsAg quantification in patients with chronic hepatitis B.The role of HBsAg quantification for monitoring natural history and treatment outcome.HBsAg quantification: useful for monitoring natural history and treatment outcome.Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analoguesHBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.How to achieve immune control in chronic hepatitis B?New paradigms in hepatitis B management: only diamonds are forever.From HCV To HBV Cure.Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion.Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy.HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy.Loss of HBsAg and antiviral treatment: from basics to clinical significance.Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir.Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B.Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.The role of HBsAg levels in the current management of chronic HBV infection.Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B.Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNAStability of hepatitis B surface antigen over time: Implications for studies using stored sera
P2860
Q26740161-FF608C1C-75C5-45F3-8D6D-9052A1ED309FQ26752475-B2BA8A7C-2383-4074-BE1B-173601D874CFQ33845546-54E02286-A523-4A1E-B9FA-5F80FA894B0DQ34674838-7519EAAD-2E7A-4062-AC55-92587FAECF8DQ35635637-37A89DE1-C82E-4036-A080-6D3D33659257Q35833216-59399D94-64EE-4834-A1F4-43AEE6F631B9Q35973806-B7F94C52-9967-41D0-B049-D63144ADF9ADQ36050504-901C9236-64A8-44D7-90DF-EBF22609CC75Q36365030-DD887922-09F8-4436-832A-2A7BF654DA09Q37343296-515345ED-01D6-472A-A73F-3C59A440E4C0Q37614037-616E17E4-089A-49AB-839E-9002B06B4AD7Q37866717-FEF84BF2-514F-49EE-9C98-F066D96F1ED9Q37966704-B57EFC8E-35B7-4AEB-A2B1-8ECBF77958C4Q37994049-D85E9ED2-2E7B-45DE-BA52-C88675DC8739Q38071397-DF745194-22D4-4626-95C9-A9475F4FB918Q38174257-88BDE51C-3146-4431-B5B9-598FF0CE258BQ38177851-F1DACDDC-ACE0-4D6A-B1A8-5628116F4BDEQ38224440-3D5CC44B-3AC1-4853-8D2D-DBFD1D12A297Q38295840-F8E78EF0-E369-40DA-88F5-B958CFA339BBQ38383489-0873BBCF-C655-41B9-BBBD-053CEC336A7FQ38588187-C5393530-764A-4DDE-9B56-CE91C245AAA7Q39067338-2C080AD7-007F-4EEC-8543-8CCFC3B035C7Q39069309-2CF413FD-3637-4B3C-817C-EB1CC72D97E2Q40118400-2B542E67-4C14-4F0B-9FE3-CBA6EF92B188Q40502187-7BCCCE70-001D-4F51-9652-7B1EB517BC4EQ41718138-9D2D753A-69B4-4A30-BA31-42D831BB38BBQ42235230-E3CB72CD-9A5F-45D7-9E28-C2CF3F218451Q42257926-3F543C69-E47F-47C0-9679-ACDE73C4B855Q42263556-183656C4-F641-4C65-AB25-6AF169AA6071Q42265719-7D33D6C0-092E-4E59-9281-792AA8ADD25FQ42279126-55D280BD-8A98-4E04-936A-B1C18029A111Q42360905-D263FD66-C445-44E9-8896-D5D100ED00A6Q45067577-02137A11-0448-495B-AF12-CFE4C58F1829Q53425320-33D6AA5A-7ECC-491F-8B83-2A9678E60836Q54217690-D0600A7F-8612-4F5C-876D-67E80D0A0BE8Q57491223-48E6CD27-A366-49F2-963C-D0972DB9368CQ58235845-A6487088-E583-4491-8D50-32138914284B
P2860
On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
On-treatment serum HBsAg level ...... chronic hepatitis B patients.
@en
On-treatment serum HBsAg level ...... chronic hepatitis B patients.
@nl
type
label
On-treatment serum HBsAg level ...... chronic hepatitis B patients.
@en
On-treatment serum HBsAg level ...... chronic hepatitis B patients.
@nl
prefLabel
On-treatment serum HBsAg level ...... chronic hepatitis B patients.
@en
On-treatment serum HBsAg level ...... chronic hepatitis B patients.
@nl
P2093
P1476
On-treatment serum HBsAg level ...... chronic hepatitis B patients.
@en
P2093
Guomin Zhao
Ruiying Gu
Shisan Bao
Xiaqiu Zhou
P356
10.1016/J.JCV.2010.02.014
P577
2010-03-15T00:00:00Z